Immunotherapy May Be Better Than Chemotherapy For Merkel Cell Carcinoma

News-Medical.Net
11 Feb, 2019 ,

According to a new study, the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy. In the 50-patient study of pembrolizumab as the initial treatment for patients with recurrent, locally advanced or metastatic Merkel cell carcinoma, more than half of the patients had long-lasting responses to the treatment & 12 of whom experienced a complete disappearance of their tumors.

Source